Bioventus Inc. Financials

BVS

Source SEC Filings (10-K/10-Q) Updated Sep 27, 2025 Currency USD FYE December

This page shows Bioventus Inc. (BVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

$573.3M

YoY+11.9%

5Y CAGR+11.0%

Bioventus Inc. generated $573.3M in revenue in fiscal year 2024. This represents an increase of 11.9% from the prior year.

EBITDA

$37.6M

YoY+254.3%

5Y CAGR-9.4%

Bioventus Inc.'s EBITDA was $37.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 254.3% from the prior year.

Free Cash Flow

$37.8M

YoY+373.4%

5Y CAGR-0.3%

Bioventus Inc. generated $37.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 373.4% from the prior year.

Net Income

-$33.5M

YoY+78.5%

Bioventus Inc. reported -$33.5M in net income in fiscal year 2024. This represents an increase of 78.5% from the prior year.

EPS (Diluted)

$-0.52

YoY+79.1%

Bioventus Inc. earned $-0.52 per diluted share (EPS) in fiscal year 2024. This represents an increase of 79.1% from the prior year.

Cash & Debt

$41.6M

YoY+12.5%

Bioventus Inc. held $41.6M in cash against $308.3M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Gross Margin

67.7%

YoY+3.7pp

5Y CAGR-5.5pp

Bioventus Inc.'s gross margin was 67.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 3.7 percentage points from the prior year.

Operating Margin

-2.1%

YoY+13.9pp

5Y CAGR-11.3pp

Bioventus Inc.'s operating margin was -2.1% in fiscal year 2024, reflecting core business profitability. This is up 13.9 percentage points from the prior year.

Net Margin

-5.9%

YoY+24.6pp

5Y CAGR-7.9pp

Bioventus Inc.'s net profit margin was -5.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 24.6 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$13.6M

YoY+1.4%

5Y CAGR+4.3%

Bioventus Inc. invested $13.6M in research and development in fiscal year 2024. This represents an increase of 1.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.0M

YoY-86.3%

5Y CAGR-15.5%

Bioventus Inc. invested $1.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 86.3% from the prior year.

BVS Income Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Revenue	$573.3M+11.9%	$512.3M0.0%	$512.1M+18.8%	$430.9M+34.2%	$321.2M-5.6%	$340.1M
Cost of Revenue	$185.1M+0.5%	$184.2M+1.7%	$181.0M+41.2%	$128.2M+46.3%	$87.6M-3.6%	$90.9M
Gross Profit	$388.2M+18.3%	$328.2M-0.9%	$331.1M+9.4%	$302.7M+29.6%	$233.5M-6.3%	$249.2M
R&D Expenses	$13.6M+1.4%	$13.4M-43.6%	$23.9M+25.3%	$19.0M+70.0%	$11.2M+1.3%	$11.1M
SG&A Expenses	$340.9M+12.2%	$303.9M-8.5%	$332.1M+30.6%	$254.3M+31.7%	$193.1M-2.7%	$198.5M
Operating Income	-$12.0M+85.3%	-$81.7M+51.1%	-$167.2M-1486.6%	$12.1M-43.2%	$21.2M-31.9%	$31.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$5.3M-6327.1%	$85K+100.2%	-$44.4M-2157.1%	-$2.0M-264.9%	$1.2M-24.4%	$1.6M
Net Income	-$33.5M+78.5%	-$156.2M+1.6%	-$158.7M-919.1%	$19.4M+18.1%	$16.4M+139.5%	$6.9M
EPS (Diluted)	$-0.52+79.1%	$-2.49+3.9%	$-2.59-1626.7%	$-0.15	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$138.7M-6.1%	$147.7M+19.2%	$123.9M-19.4%	$153.6M+10.6%	$139.0M-8.1%	$151.2M+16.8%	$129.5M-4.4%	$135.4M
Cost of Revenue	$44.4M-2.5%	$45.6M+11.6%	$40.8M-19.9%	$51.0M+12.3%	$45.4M-4.6%	$47.6M+15.8%	$41.1M-16.4%	$49.1M
Gross Profit	$94.2M-7.7%	$102.1M+22.9%	$83.1M-19.1%	$102.7M+9.7%	$93.6M-9.7%	$103.6M+17.3%	$88.4M+2.4%	$86.3M
R&D Expenses	$2.9M-7.8%	$3.2M+5.3%	$3.0M+1.8%	$3.0M-23.0%	$3.8M-8.7%	$4.2M+60.3%	$2.6M-19.5%	$3.3M
SG&A Expenses	$78.7M-0.6%	$79.1M+7.6%	$73.5M-12.5%	$84.0M+3.1%	$81.5M-15.7%	$96.7M+22.7%	$78.8M+0.5%	$78.4M
Operating Income	$11.3M-38.7%	$18.4M+277.2%	$4.9M-55.4%	$10.9M+199.4%	$3.6M+111.6%	-$31.5M-738.7%	$4.9M+323.0%	$1.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$664K-36.2%	$1.0M+1195.8%	-$95K-117.3%	$550K-6.6%	$589K+108.0%	-$7.3M-909.2%	$907K+220.9%	-$750K
Net Income	$3.2M-57.7%	$7.5M+382.9%	-$2.6M-220.1%	$2.2M+142.5%	-$5.2M+79.9%	-$25.7M-425.2%	-$4.9M+19.8%	-$6.1M
EPS (Diluted)	$0.05-54.5%	$0.11+375.0%	$-0.04-200.0%	$0.04+150.0%	$-0.08+80.0%	$-0.40-400.0%	$-0.08-14.3%	$-0.07

BVS Balance Sheet

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Total Assets	$728.0M-10.2%	$810.9M-40.9%	$1.4B+12.0%	$1.2B+147.9%	$494.5M	N/A
Current Assets	$275.6M+2.8%	$268.0M-1.7%	$272.6M+3.6%	$263.1M+24.2%	$211.8M	N/A
Cash & Equivalents	$41.6M+12.5%	$37.0M+22.5%	$30.2M-31.3%	$43.9M-49.4%	$86.8M	N/A
Inventory	$92.5M+1.3%	$91.3M+7.7%	$84.8M+37.4%	$61.7M+111.8%	$29.1M	N/A
Accounts Receivable	$127.4M+3.7%	$122.8M-9.9%	$136.3M+9.1%	$125.0M+41.5%	$88.3M	N/A
Goodwill	$7.5M0.0%	$7.5M0.0%	$7.5M-94.9%	$147.6M+196.4%	$49.8M	N/A
Total Liabilities	$542.4M-8.0%	$589.8M-38.6%	$960.4M+55.4%	$618.2M+76.5%	$350.3M	N/A
Current Liabilities	$210.4M+19.9%	$175.5M-42.3%	$304.0M+68.1%	$180.9M+47.5%	$122.6M	N/A
Long-Term Debt	$308.3M-16.0%	$367.0M-4.7%	$385.0M+13.4%	$339.6M+95.9%	$173.4M	N/A
Total Equity	$147.9M-33.1%	$221.1M-46.4%	$412.2M-32.2%	$607.7M+321.5%	$144.2M	N/A
Retained Earnings	-$357.7M-11.2%	-$321.5M-94.5%	-$165.3M-2403.9%	-$6.6M	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$701.6M-0.7%	$706.8M+2.2%	$691.4M-5.0%	$728.0M-5.4%	$769.5M-2.9%	$792.2M-0.3%	$794.2M-2.1%	$810.9M
Current Assets	$280.9M+2.1%	$275.2M+10.4%	$249.4M-9.5%	$275.6M-7.7%	$298.7M-3.3%	$308.9M+16.2%	$265.9M-0.8%	$268.0M
Cash & Equivalents	$42.2M+28.1%	$32.9M+44.3%	$22.8M-45.2%	$41.6M-3.5%	$43.1M+34.6%	$32.0M+27.1%	$25.2M-31.9%	$37.0M
Inventory	$96.3M-0.2%	$96.5M+2.6%	$94.0M+1.7%	$92.5M+2.7%	$90.0M+2.8%	$87.6M-9.7%	$97.0M+6.2%	$91.3M
Accounts Receivable	$130.4M-1.5%	$132.4M+12.1%	$118.1M-7.3%	$127.4M+4.5%	$121.9M-11.2%	$137.3M+9.4%	$125.5M+2.2%	$122.8M
Goodwill	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M0.0%	$7.5M
Total Liabilities	$494.3M-2.2%	$505.5M-0.1%	$505.9M-6.7%	$542.4M-6.9%	$582.7M-3.4%	$603.1M+4.6%	$576.8M-2.2%	$589.8M
Current Liabilities	$161.8M-12.9%	$185.7M+6.3%	$174.8M-16.9%	$210.4M-0.5%	$211.5M-8.6%	$231.5M+33.5%	$173.3M-1.2%	$175.5M
Long-Term Debt	$311.3M+4.5%	$297.9M-3.5%	$308.6M+0.1%	$308.3M-10.6%	$345.0M+0.1%	$344.7M-3.0%	$355.4M-3.2%	$367.0M
Total Equity	$166.1M-17.5%	$201.3M+8.5%	$185.5M+25.4%	$147.9M-20.8%	$186.8M-1.2%	$189.1M-13.0%	$217.4M-1.7%	$221.1M
Retained Earnings	-$349.7M+0.9%	-$352.8M+2.1%	-$360.3M-0.7%	-$357.7M-0.8%	-$354.9M-1.4%	-$350.1M-7.4%	-$326.1M-1.4%	-$321.5M

BVS Cash Flow Statement

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Operating Cash Flow	$38.8M+152.8%	$15.3M+213.3%	-$13.5M-158.9%	$23.0M-68.0%	$71.8M+76.4%	$40.7M
Capital Expenditures	$1.0M-86.3%	$7.4M+398.1%	$1.5M-89.1%	$13.5M-18.5%	$16.6M+607.9%	$2.3M
Free Cash Flow	$37.8M+373.4%	$8.0M+153.2%	-$15.0M-258.5%	$9.5M-82.8%	$55.2M+43.9%	$38.4M
Investing Cash Flow	$23.0M+45.3%	$15.8M+113.6%	-$116.4M+59.0%	-$283.8M-1284.2%	-$20.5M-159.1%	-$7.9M
Financing Cash Flow	-$54.6M-104.8%	-$26.7M-142.9%	$62.1M-77.3%	$273.4M+1024.5%	-$29.6M-170.0%	-$11.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	-$19.3M	N/A	N/A	N/A	-$6.0M	N/A
Capital Expenditures	N/A	N/A	$826K	N/A	N/A	N/A	$291K	N/A
Free Cash Flow	N/A	N/A	-$20.2M	N/A	N/A	N/A	-$6.3M	N/A
Investing Cash Flow	N/A	N/A	-$826K	N/A	N/A	N/A	-$1.0M	N/A
Financing Cash Flow	N/A	N/A	$947K	N/A	N/A	N/A	-$4.2M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BVS Financial Ratios

Metric	FY24	FY24	FY24	FY23	FY22	FY21
Gross Margin	67.7%+3.7pp	64.1%-0.6pp	64.6%-5.6pp	70.3%-2.5pp	72.7%-0.6pp	73.3%
Operating Margin	-2.1%+13.9pp	-16.0%+16.7pp	-32.7%-35.5pp	2.8%-3.8pp	6.6%-2.6pp	9.2%
Net Margin	-5.9%+24.6pp	-30.5%+0.5pp	-31.0%-35.5pp	4.5%-0.6pp	5.1%+3.1pp	2.0%
Return on Equity	N/A	N/A	N/A	3.2%-8.2pp	11.4%	N/A
Return on Assets	-4.6%+14.7pp	-19.3%-7.7pp	-11.6%-13.1pp	1.6%-1.7pp	3.3%	N/A
Current Ratio	1.31-0.2	1.53+0.6	0.90-0.6	1.45-0.3	1.73	N/A
Debt-to-Equity	2.08+0.4	1.66+0.7	0.93+0.4	0.56-0.6	1.20	N/A
FCF Margin	6.6%+5.0pp	1.6%+4.5pp	-2.9%-5.1pp	2.2%-15.0pp	17.2%+5.9pp	11.3%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	68.0%-1.2pp	69.1%+2.1pp	67.0%+0.2pp	66.8%-0.5pp	67.3%-1.2pp	68.5%+0.3pp	68.3%+4.5pp	63.7%
Operating Margin	8.1%-4.3pp	12.4%+8.5pp	3.9%-3.2pp	7.1%+4.5pp	2.6%+23.4pp	-20.8%-24.6pp	3.8%+3.0pp	0.9%
Net Margin	2.3%-2.8pp	5.1%+7.2pp	-2.1%-3.6pp	1.4%+5.1pp	-3.7%+13.3pp	-17.0%-13.2pp	-3.8%+0.7pp	-4.5%
Return on Equity	1.9%-1.8pp	3.7%	N/A	1.5%	N/A	N/A	N/A	N/A
Return on Assets	0.4%-0.6pp	1.1%+1.4pp	-0.4%-0.7pp	0.3%+1.0pp	-0.7%+2.6pp	-3.2%-2.6pp	-0.6%+0.1pp	-0.8%
Current Ratio	1.74+0.3	1.48+0.1	1.43+0.1	1.31-0.1	1.41+0.1	1.33-0.2	1.530.0	1.53
Debt-to-Equity	1.87+0.4	1.48-0.2	1.66-0.4	2.08+0.2	1.85+0.0	1.82+0.2	1.63-0.0	1.66
FCF Margin	N/A	N/A	-16.3%	N/A	N/A	N/A	-4.9%	N/A

Financial Health Signals

Financial Profile 32/100

Profitability

Growth

Leverage

Liquidity

Cash Flow

Returns

N/A

Based on FY2024 annual data. Scores normalized against common benchmarks.

Piotroski F-Score Neutral

6/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Mixed

-1.16x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Similar Companies

STANDARD BIOTOOLS INC LAB

$426.9M

Treace Medical Concepts, Inc. TMCI

$121.1M

Surmodics Inc SRDX

$614.5M

Orthofix Med Inc OFIX

$525.5M

Avanos Medical AVNS

$685.1M

Frequently Asked Questions

What is Bioventus Inc.'s annual revenue?

Bioventus Inc. (BVS) reported $573.3M in total revenue for fiscal year 2024. This represents a 11.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bioventus Inc.'s revenue growing?

Bioventus Inc. (BVS) revenue grew by 11.9% year-over-year, from $512.3M to $573.3M in fiscal year 2024.

Is Bioventus Inc. profitable?

No, Bioventus Inc. (BVS) reported a net income of -$33.5M in fiscal year 2024, with a net profit margin of -5.9%.

What is Bioventus Inc.'s earnings per share (EPS)?

Bioventus Inc. (BVS) reported diluted earnings per share of $-0.52 for fiscal year 2024. This represents a 79.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Bioventus Inc.'s EBITDA?

Bioventus Inc. (BVS) had EBITDA of $37.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Bioventus Inc. have?

As of fiscal year 2024, Bioventus Inc. (BVS) had $41.6M in cash and equivalents against $308.3M in long-term debt.

What is Bioventus Inc.'s gross margin?

Bioventus Inc. (BVS) had a gross margin of 67.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bioventus Inc.'s operating margin?

Bioventus Inc. (BVS) had an operating margin of -2.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Bioventus Inc.'s net profit margin?

Bioventus Inc. (BVS) had a net profit margin of -5.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Bioventus Inc.'s free cash flow?

Bioventus Inc. (BVS) generated $37.8M in free cash flow during fiscal year 2024. This represents a 373.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bioventus Inc.'s operating cash flow?

Bioventus Inc. (BVS) generated $38.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Bioventus Inc.'s total assets?

Bioventus Inc. (BVS) had $728.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Bioventus Inc.'s capital expenditures?

Bioventus Inc. (BVS) invested $1.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Bioventus Inc. spend on research and development?

Bioventus Inc. (BVS) invested $13.6M in research and development during fiscal year 2024.

What is Bioventus Inc.'s current ratio?

Bioventus Inc. (BVS) had a current ratio of 1.31 as of fiscal year 2024, which is considered adequate.

What is Bioventus Inc.'s debt-to-equity ratio?

Bioventus Inc. (BVS) had a debt-to-equity ratio of 2.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bioventus Inc.'s return on assets (ROA)?

Bioventus Inc. (BVS) had a return on assets of -4.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Bioventus Inc.'s Piotroski F-Score?

Bioventus Inc. (BVS) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are Bioventus Inc.'s earnings high quality?

Bioventus Inc. (BVS) has an earnings quality ratio of -1.16x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

How financially healthy is Bioventus Inc.?

Bioventus Inc. (BVS) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.